Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single Arm, Safety Lead-in, Multicenter, Investigator Initiated Trial of Combination of Durvalumab , An Immune Checkpoint Inhibitor, and BVAC-C, A Cell-based Immunotherapeutic Vaccine, in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy

NCT04800978 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04800978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04800978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single Arm, Safety Lead-in, Multicenter, Investigator Initiated Trial of Combination of Durvalumab , An Immune Checkpoint Inhibitor, and BVAC-C, A Cell-based Immunotherapeutic Vaccine, in Patients With HPV 16 or 18 Positive Cervical Cancer Failure to First-Line Platinum-based Chemotherapy
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
June 14, 2021
Completion date
August 31, 2024
Enrollment
37 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer